Companies Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals (CRBP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Corbus Pharmaceuticals Holdings, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,137,622FY2023
- $4,245,438FY2024
- $3,750,125FY2025
CEO total pay was $3,750,125 in fiscal 2025, down from $4,245,438 in fiscal 2024.
FY2025: salary $646,566 · bonus $373,682 · stock awards $666,699 · option awards $2,039,294
Order CRBP
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Yuval Cohen | $646,566 | $373,682 | $666,699 | $2,039,294 | $0 | $0 | $23,884 | $3,750,125 |
| Chief Executive Officer and Director | ||||||||
| Dominic Smethurst | 519,313 | 168,078 | 266,288 | 812,866 | 0 | 0 | 33,597 | 1,800,142 |
| Chief Medical Officer | ||||||||
| Sean Moran | 481,137 | 185,382 | 269,225 | 824,453 | 0 | 0 | 29,226 | 1,789,423 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Yuval Cohen | $3,750,125 | $4,245,438 | $1,137,622 | ↓ −495,313 |
| Dominic Smethurst | 1,800,142 | 2,892,972 | — | ↓ −1,092,830 |
| Sean Moran | 1,789,423 | 2,429,505 | 717,256 | ↓ −640,082 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract and retain highly skilled personnel in the competitive life sciences industry. Executive compensation consists of base salary, annual discretionary bonus (targeted at 60% of salary for CEO, 40% for other NEOs), and equity awards (stock options and RSUs), with the goal of aligning executive interests with stockholder value creation and rewarding individual and company performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | False |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sean Moran | Option | — | — | — | — | — | $824,453 |
| Sean Moran | RSU | — | — | — | — | — | 269,225 |
| Yuval Cohen | Option | — | — | — | — | — | 2,039,294 |
| Dominic Smethurst | RSU | — | — | — | — | — | 266,288 |
| Dominic Smethurst | Option | — | — | — | — | — | 812,866 |
| Yuval Cohen | RSU | — | — | — | — | — | 666,699 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sean Moran | $269,225 | $0 | $824,453 | 0.0% |
| Yuval Cohen | 666,699 | 0 | 2,039,294 | 0.0% |
| Dominic Smethurst | 266,288 | 0 | 812,866 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Moran | Option | 748 | 14.1 | — |
| Yuval Cohen | Option | 2,070 | 14.1 | — |
| Sean Moran | Option | 9,087 | 4.26 | — |
| Yuval Cohen | Option | 19,343 | 4.26 | — |
| Sean Moran | Option | 21,762 | 23 | — |
| Dominic Smethurst | Option | 27,084 | 26.07 | — |
| Dominic Smethurst | PSU | 27,200 | — | 221,408 |
| Sean Moran | PSU | 27,500 | — | 223,850 |
| Sean Moran | PSU | 30,132 | — | 245,274 |
| Dominic Smethurst | PSU | 37,500 | — | 305,250 |
| Yuval Cohen | Option | 40,055 | 23 | — |
| Yuval Cohen | PSU | 55,461 | — | 451,453 |
| Yuval Cohen | PSU | 68,100 | — | 554,334 |
| Dominic Smethurst | Option | 91,200 | 9.79 | — |
| Sean Moran | Option | 92,500 | 9.79 | — |
| Yuval Cohen | Option | 228,800 | 9.79 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Rachelle JacquesIndependent · Board Chair · Audit · Nominating/Governance | $72,582 | $35,616 | $107,584 | — | $0 | $215,782 |
| John JenkinsIndependent · Audit · Compensation (Chair) | 65,000 | 35,616 | 107,584 | — | 0 | 208,200 |
| Winston KungIndependent · Audit (Chair) | 60,000 | 35,616 | 107,584 | — | 0 | 203,200 |
| Alan HolmerIndependent · Departed during FY | 57,418 | 35,616 | 107,584 | — | 0 | 200,618 |
| Yong BenIndependent · Compensation · Nominating/Governance | 52,500 | 35,616 | 107,584 | — | 0 | 195,700 |
| Anne AltmeyerIndependent · Compensation · Nominating/Governance (Chair) | 50,646 | 35,616 | 107,584 | — | 0 | 193,846 |
| Peter SalzmannIndependent · Not standing for re-election · Departed during FY | 16,690 | — | — | — | 0 | 16,690 |
| Yuval CohenEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $374,836 |
| Equity awards (grant-date value) | $213,696 |
| All other compensation | $0 |
| Total cost of the board | $588,532 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Corbus Pharmaceuticals as a peer
Companies that benchmark against CRBP
1 company names CRBP as a compensation peer
The list of companies that name CRBP as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corbus Pharmaceuticals Holdings, Inc. | 2025 | Yuval Cohen | $646,566 | $666,699 | $2,039,294 | $0 | $3,750,125 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-13 | 9,325,932 | 721,442 | 26,696 | 92.82% | Passed |
| 2025 | 2025-05-15 | 6,519,904 | 215,784 | 11,102 | 96.8% | Passed |
| 2024 | 2024-05-16 | 6,593,949 | 44,363 | 9,862 | 99.33% | Passed |
| 2023 | 2023-05-18 | 244,160 | 60,487 | 9,370 | 80.15% | Passed |
| 2021 | 2021-06-17 | 36,346,860 | 4,599,776 | 634,982 | 88.77% | Passed |
| 2020 | 2020-05-20 | 18,992,387 | 2,303,630 | 323,179 | 89.18% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-13 | 92.82%a |
| 2025 | 2025-05-15 | 96.8%b |
| 2024 | 2024-05-16 | 99.33%c |
a. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “As a result, abstentions and "broker non-votes" (see below), if any, will not affect the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Brent Pfeiffenberger | Director | 2026-05-19 | A | 7,500 | $0 | $0 | RSU | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Yong Ben | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Jenkins | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Yong Ben | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| Winston Kung | Director | 2026-05-19 | A | 3,800 | 0 | 0 | RSU | Form 4 ↗ |
| John Jenkins | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Winston Kung | Director | 2026-05-19 | A | 12,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brent Pfeiffenberger | Director | 2026-05-19 | A | 24,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-05-21 | A | 58,300 | 0 | 0 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-05-21 | A | 192,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-06-02 | A | 4,500 | 7 | 32,999 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-06-03 | A | 9,000 | 8 | 68,220 | Common | Form 4 ↗ |
| Winston Kung | Director | 2026-06-10 | D | 2,026 | 8 | 16,033 | Common | Form 4 ↗ |
| John Jenkins | Director | 2026-06-10 | D | 4,800 | 8 | 37,986 | Common | Form 4 ↗ |
| Anne Altmeyer | Director | 2026-06-10 | D | 2,412 | 8 | 19,088 | Common | Form 4 ↗ |
| Yuval Cohen | Director | 2026-08-07 | D | 17,000 | 10 | 171,396 | Common | Form 4 ↗ |
| Sean Moran | Chief Financial Officer | 2026-08-07 | D | 12,000 | 10 | 120,971 | Common | Form 4 ↗ |
| Nishant C. Saxena | Chief Business Officer | 2026-08-11 | A | 2,600 | 10 | 25,036 | Common | Form 4 ↗ |
| Leonardo Viana Nicacio | Chief Medical Officer | 2026-08-16 | A | 191,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonardo Viana Nicacio | Chief Medical Officer | 2026-08-16 | A | 58,333 | 0 | 0 | Common | Form 4 ↗ |
| Yong Ben | Director | 2026-09-14 | D | 2,000 | 8 | 15,683 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (50 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Yuval Cohen. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · page 16. As printed: 3,750,125. View filing ↗
- Section 01, Dominic Smethurst. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · page 16. As printed: 1,800,142. View filing ↗
- Section 01, Sean Moran. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · page 16. As printed: 1,789,423. View filing ↗
- Section 03, Sean Moran Option. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sean Moran RSU. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Yuval Cohen Option. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Dominic Smethurst RSU. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Dominic Smethurst Option. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Yuval Cohen RSU. DEF 14A, filed 2026-04-02. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-09. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Rachelle Jacques. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 215,782. View filing ↗
- Section 08, John Jenkins. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 208,200. View filing ↗
- Section 08, Winston Kung. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 203,200. View filing ↗
- Section 08, Alan Holmer. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 200,618. View filing ↗
- Section 08, Yong Ben. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 195,700. View filing ↗
- Section 08, Anne Altmeyer. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 193,846. View filing ↗
- Section 08, Peter Salzmann. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 16,690. View filing ↗
- Section 08, Yuval Cohen. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Brent Pfeiffenberger 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anne Altmeyer 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachelle Jacques 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yong Ben 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anne Altmeyer 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Jenkins 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yong Ben 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Winston Kung 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Jenkins 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachelle Jacques 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Winston Kung 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent Pfeiffenberger 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nishant C. Saxena 2026-05-21. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nishant C. Saxena 2026-05-21. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nishant C. Saxena 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nishant C. Saxena 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Winston Kung 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Jenkins 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anne Altmeyer 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuval Cohen 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Moran 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nishant C. Saxena 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonardo Viana Nicacio 2026-08-16. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonardo Viana Nicacio 2026-08-16. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yong Ben 2026-09-14. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-14. Item 5.07 · say-on-pay result. As reported: 92.82% (votes for as printed: 9,325,932). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-19. Item 5.07 · say-on-pay result. As reported: 96.8% (votes for as printed: 6,519,904). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-20. Item 5.07 · say-on-pay result. As reported: 99.33% (votes for as printed: 6,593,949). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 374,836 + equity 213,696 + all other 0 = 588,532, summed across the director compensation table rows.
- Corbus Pharmaceuticals Holdings, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Corbus Pharmaceuticals Holdings, Inc.'s own proxy. As printed: 3,750,125. View filing ↗